JP2006510740A - 出血と関連した神経系障害を治療する方法 - Google Patents

出血と関連した神経系障害を治療する方法 Download PDF

Info

Publication number
JP2006510740A
JP2006510740A JP2005507039A JP2005507039A JP2006510740A JP 2006510740 A JP2006510740 A JP 2006510740A JP 2005507039 A JP2005507039 A JP 2005507039A JP 2005507039 A JP2005507039 A JP 2005507039A JP 2006510740 A JP2006510740 A JP 2006510740A
Authority
JP
Japan
Prior art keywords
tudca
bleeding
administration
bcl
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005507039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510740A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ. ステア,クリフォード
シー. ロウ,ウォルター
エミ.ペー. ロドリゲス,セシリア
ナン,チェンホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2006510740A publication Critical patent/JP2006510740A/ja
Publication of JP2006510740A5 publication Critical patent/JP2006510740A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2005507039A 2002-11-07 2003-10-08 出血と関連した神経系障害を治療する方法 Pending JP2006510740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42521002P 2002-11-07 2002-11-07
US45161503P 2003-03-03 2003-03-03
PCT/US2003/031989 WO2004043342A2 (en) 2002-11-07 2003-10-08 Methods of treating injuries of the nervous system associated with hemorrhage

Publications (2)

Publication Number Publication Date
JP2006510740A true JP2006510740A (ja) 2006-03-30
JP2006510740A5 JP2006510740A5 (cg-RX-API-DMAC7.html) 2006-11-24

Family

ID=32314576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005507039A Pending JP2006510740A (ja) 2002-11-07 2003-10-08 出血と関連した神経系障害を治療する方法

Country Status (8)

Country Link
US (1) US20060135494A1 (cg-RX-API-DMAC7.html)
EP (1) EP1575578B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006510740A (cg-RX-API-DMAC7.html)
KR (1) KR20050103185A (cg-RX-API-DMAC7.html)
AT (1) ATE451108T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003275495A1 (cg-RX-API-DMAC7.html)
DE (1) DE60330501D1 (cg-RX-API-DMAC7.html)
WO (1) WO2004043342A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US20060204481A1 (en) * 2003-04-02 2006-09-14 Steer Clifford J Methods of promoting cell viability
ES2339790T3 (es) * 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
DE602005027727D1 (de) 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
JP2008530100A (ja) * 2005-02-10 2008-08-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 視覚障害の治療方法
AU2007230989A1 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
KR20180029317A (ko) * 2016-09-12 2018-03-21 경상대학교산학협력단 간손상 예방, 개선 또는 치료용 조성물
KR101953298B1 (ko) * 2017-07-18 2019-02-28 의료법인 성광의료재단 우르소데옥시콜산을 함유하는 염증성 질환 또는 척수 손상 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011708A2 (en) * 2000-08-04 2002-02-14 Symphar S.A. Methods for inducing apolipoprotein e secretion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138971T3 (es) * 1991-07-03 2000-02-01 Otsuka Pharma Co Ltd Regulador de la apoptosis.
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
WO1999015179A1 (en) * 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO1999043336A1 (en) * 1998-02-27 1999-09-02 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011708A2 (en) * 2000-08-04 2002-02-14 Symphar S.A. Methods for inducing apolipoprotein e secretion

Also Published As

Publication number Publication date
HK1086479A1 (zh) 2006-09-22
EP1575578A2 (en) 2005-09-21
KR20050103185A (ko) 2005-10-27
DE60330501D1 (de) 2010-01-21
WO2004043342A3 (en) 2004-07-15
AU2003275495A8 (en) 2004-06-03
EP1575578A4 (en) 2007-10-10
EP1575578B1 (en) 2009-12-09
ATE451108T1 (de) 2009-12-15
WO2004043342A2 (en) 2004-05-27
AU2003275495A1 (en) 2004-06-03
US20060135494A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
ES2368299T3 (es) Uso de un beta-bloqueante para la fabricación de un medicamento para el tratamiento de hemangiomas.
Wakade et al. Curcumin attenuates vascular inflammation and cerebral vasospasm after subarachnoid hemorrhage in mice
MXPA01005598A (es) Metodo y composicion para el tratamiento de cancer que utiliza aceites esenciales vegetales naturales con moduladores de transduccion de senal.
Zhang et al. Isosteviol sodium protects against permanent cerebral ischemia injury in mice via inhibition of NF-κB–mediated inflammatory and apoptotic responses
TW201002315A (en) Anti-tumoural effects of cannabinoid combinations
JP2019537628A (ja) 併用療法
JP2019503401A (ja) ピロロキノリンキノン、その誘導体及び/又は塩の乾燥症候群における使用ならびに医薬組成物
JP2011505385A (ja) 良性前立腺過形成の治療のための医薬製剤
JP2002544229A (ja) 癌の化学的予防および治療のために組み合わせたdfmoおよびセレコキシブ
KR102358632B1 (ko) 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
US11376233B2 (en) Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss
JP6708869B2 (ja) 神経系疾患治療剤
KR20020035855A (ko) 약용인삼을 포함하는 뇌세포 또는 신경세포 보호제
EP1575578B1 (en) Methods of treating injuries of the nervous system associated with hemorrhage
JP2003530353A (ja) オルチプラズの肝繊維化及び肝硬変症進行の予防及び治療剤としての使用方法、及びオルチプラズを主成分として含有する製薬組成物
Santing et al. Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma
JP2025507192A5 (cg-RX-API-DMAC7.html)
Yu et al. Effects of MPSS and a potent iNOS inhibitor on traumatic spinal cord injury
US20230255943A1 (en) Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
KR20180035739A (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
CN100421656C (zh) 乌索脱氧胆酸在制备治疗与出血相关的神经系统损伤的药物中的用途
KR20010079495A (ko) 혈관 보호제
HK1086479B (en) The use of a ursodeoxycholic acid in the preparation of a medicament for treating a hemorrhage-associated nervous system injury
JP2006504769A (ja) 病理学的プロセスに関する遺伝子発現を制御するためのキナゾリノン組成物
KR20230061860A (ko) 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100727